TY  - JOUR
AU  - Santos, C
AU  - Azuara, D
AU  - Viéitez, J M
AU  - Páez, D
AU  - Falcó, E
AU  - Élez, E
AU  - López-López, C
AU  - Valladares, M
AU  - Robles-Díaz, L
AU  - García-Alfonso, P
AU  - Bugés, C
AU  - Durán, G
AU  - Salud, A
AU  - Navarro, V
AU  - Capellá, G
AU  - Aranda, E
AU  - Salazar, R
PY  - 2019
DO  - 10.1093/annonc/mdz082
UR  - https://hdl.handle.net/10668/28330
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Several studies show the importance of accurately quantifying not only KRAS and other low-abundant mutations because benefits of anti-EGFR therapies may depend on certain sensitivity thresholds. We assessed whether ultra-selection of patients using a...
LA  - en
KW  - FOLFIRI
KW  - PCR
KW  - digital PCR
KW  - metastatic colorectal cancer
KW  - panitumumab
KW  - patient selection
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers, Tumor
KW  - Camptothecin
KW  - Class I Phosphatidylinositol 3-Kinases
KW  - Colorectal Neoplasms
KW  - Fluorouracil
KW  - GTP Phosphohydrolases
KW  - Genotype
KW  - Humans
KW  - Leucovorin
KW  - Male
KW  - Membrane Proteins
KW  - Middle Aged
KW  - Neoplasm Metastasis
KW  - Panitumumab
KW  - Prospective Studies
KW  - Proto-Oncogene Proteins B-raf
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Survival Rate
TI  - Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
TY  - research article
VL  - 30
ER  -